Norges Bank
ZNTL icon

Norges Bank’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Norges Bank’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-71,527
Closed -$293K – 1972
2024
Q2 		$293K Sell
71,527
-71,429
-50% -$798K ﹤0.01% 1905
2024
Q1 		$2.25M Sell
142,956
-21,386
-13% -$294K ﹤0.01% 1726
2023
Q4 		$2.49M Hold
164,342
– – ﹤0.01% 1776
2023
Q3 		$3.3M Sell
164,342
-3,400
-2% -$86.3K ﹤0.01% 1760
2023
Q2 		$4.73M Sell
167,742
-169,900
-50% -$4.08M ﹤0.01% 1732
2023
Q1 		$5.81M Buy
337,642
+105,654
+46% +$2.14M ﹤0.01% 1714
2022
Q4 		$4.67M Hold
231,988
– – ﹤0.01% 1797
2022
Q3 		$5.02M Sell
231,988
-100,056
-30% -$2.74M ﹤0.01% 1765
2022
Q2 		$9.33M Buy
332,044
+237,294
+250% +$6.29M ﹤0.01% 1585
2022
Q1 		$4.37M Buy
94,750
+40,967
+76% +$2.21M ﹤0.01% 1895
2021
Q4 		$4.52M Hold
53,783
– – ﹤0.01% 1924
2021
Q3 		$3.58M Buy
53,783
+13,877
+35% +$801K ﹤0.01% 1971
2021
Q2 		$2.12M Buy
39,906
+10,980
+38% +$588K ﹤0.01% 2013
2021
Q1 		$1.25M Buy
28,926
+19,082
+194% +$822K ﹤0.01% 2031
2020
Q4 		$511K Buy
+9,844
New +$444K ﹤0.01% 2080

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank's ZNTL Position: Q3 2024 in Review

Norges Bank sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 71,527 shares — an estimated $293K sold.

Norges Bank first reported a position in ZNTL in Q4 2020 and held it in 15 quarters. The position peaked at $9.33M in Q2 2022. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Norges Bank reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Norges Bank sold 71,527 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $293K.
  • Norges Bank first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 15 quarters.
  • Norges Bank's Zentalis Pharmaceuticals position peaked at $9.33M in Q2 2022.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Norges Bank's 13F filing for Q3 2024, filed 13 Nov 2024.